Verified Nov 2026
Other
·

Allschwil, Basel-Landschaft
·
Since 2017
Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.
Idorsia at a glance
Revenue
$250-500M
Est. band
Employees
500-1,000
Founded
2017
Headquarters
Allschwil, Basel-Landschaft
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Overview
Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.
At a glance
Attribute | Detail |
|---|---|
Founded | 2017 |
Headquarters | Allschwil, Basel-Landschaft |
Employees | 500-1,000 |
Revenue | $250-500M (estimated) |
What Idorsia makes
The company develops small-molecule therapeutics spanning central nervous system disorders, cardiovascular disease, immunological conditions, and orphan diseases, with a marketed product and multiple late-stage investigational compounds.
Latest developments
2026-11-03 — Idorsia | Media releases (idorsia.com)
2026-07-27 — Jamjoom pharma announces strategic partnership with Idorsia | ZAWYA (zawya.com)
2026-06-09 — BioPharma Credit stellt Idorsia Darlehen von bis zu 75 Mio. CHF bereit | MarketScreener Schweiz (marketscreener.com)
2026-04-28 — Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ (globenewswire.com)
2026-02-26 — Idorsia reports strong 2025 results with QUVIVIQ sales more (globenewswire.com)
2025-10-10 — Idorsia successfully completes an upsized offering of (globenewswire.com)
Company details
Idorsia announced a strategic partnership with Jamjoom Pharma in 2026, expanding its commercial reach in targeted markets. Idorsia was founded in 2017, has an estimated 500-1,000 employees, and is headquartered in Allschwil, Basel-Landschaft.
Frequently asked questions
What does Idorsia do?
Idorsia is a Swiss biopharmaceutical company founded in 2017 and headquartered in Allschwil, near Basel. The company operates in the 500–1,000 employee range with estimated revenue of $250–500 million. Idorsia discovers, develops, and commercializes small-molecule drugs targeting the central nervous system, cardiovascular disorders, immunological conditions, and orphan diseases. The company's approved product Quviviq treats insomnia, and it maintains a pipeline including Aprocitentan for resistant hypertension and other compounds in clinical development.
Where is Idorsia headquartered?
Idorsia is headquartered in Allschwil, Basel-Landschaft (91 Hegenheimermattweg, Allschwil, Basel-Landschaft, 4123).
When was Idorsia founded?
Idorsia was founded in 2017.
How big is Idorsia?
Idorsia has an estimated 500-1,000 employees, with revenue in the $250-500M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
